Pure Global
NCT06403787

Effect of Aerobic Training and Ginkgo Biloba on Lipids Levels in HIV-positive Patients Undergoing Antiretroviral Treatment

Effect of Implementing an Aerobic Training Program and Administering Ginkgo Biloba Extract on Plasma Concentrations of LDL and HDL in HIV Positive Patients Undergoing Antiretroviral Treatment at the HIV Unit of Hospital Civil Fray Antonio Alcalde
University of Guadalajara·Phase 2/3·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Human Immunodeficiency Virus
Drug/Device/Intervention
Aerobic exercise + Ginkgo Biloba Extract
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of Guadalajara
Location
Guadalajara, Mexico
Timeline & enrollment
Phase
Phase 2/3
Start date
May 01, 2022
End date
Apr 01, 2024
Enrollment
28 participants
Primary outcome

Comparison of changes in serum lipid levels.

Summary

The administration of antiretroviral drugs (ART) has significantly prolonged the life
 expectancy of people living with human immunodeficiency virus (HIV) and delayed the
 progression towards Acquired Immune Deficiency Syndrome (AIDS). However, this has led to the
 emergence of other conditions, such as dyslipidemia, among individuals undergoing ART.
 Dyslipidemia is commonly managed with statin therapy, which has not been reported to have
 pharmacological interactions with ART. Additionally, ginkgo biloba extract (GBS) has been
 observed to improve blood lipid concentrations, and aerobic exercise training (EXA)
 interventions have shown positive modifications in these values.
 
 Given this context, the present study aims to investigate the potential positive effects of
 an aerobic training program and the consumption of ginkgo biloba extract on plasma lipid
 concentrations in HIV-positive individuals. The study seeks to provide insights into novel
 strategies for managing dyslipidemia in this population.

ICD-10 classifications
Human immunodeficiency virus [HIV] diseaseUnspecified human immunodeficiency virus [HIV] diseaseHuman immunodeficiency virus [HIV] disease resulting in other conditionsHuman immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseasesAsymptomatic human immunodeficiency virus [HIV] infection status
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06403787
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06403787 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by University of Guadalajara and is currently Completed. The study focuses on Human Immunodeficiency Virus. Target enrollment is 28 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.